Chronic Hepatitis

Top Story

Chronic HBV prevalent among non-high-risk populations across world

July 31, 2015

In a new study, researchers found a prevalence of chronic hepatitis B virus infection across various non–high-risk populations across the world, indicating strategies of prevention and control are still needed to combat the infection, according to findings published in The Lancet.

“Chronic hepatitis B virus infection continues to be a major public health issue worldwide, despite the availability of an effective vaccine and potent antiviral treatments,” the researchers wrote. “[Currently] there are no up-to-date global systematic reviews reporting country-level chronic HBV prevalence [and] previous systematic reviews on HBV prevalence were limited in scope.”

AbbVie announces Viekira Pak sales reach nearly $400 million

July 31, 2015
AbbVie announced second quarter financial results and showed Viekira Pak global sales were nearly $400 million, which assisted the company in reaching an overall global…

Gilead's product sales soar due to Harvoni

July 30, 2015
Gilead Sciences announced second quarter financial results and showed an increase of $1.7 billion for overall product sales and an increase of $1.6 billion in antiviral…
In the Journals

Cirrhosis in HCV patients may be underdiagnosed

July 30, 2015
Cirrhosis was found to be underdiagnosed among patients with hepatitis C virus infection enrolled in the Chronic Hepatitis Cohort Study, according to new study…
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Meeting News Coverage Video
thumbnail for video 3899432251001

New HCV treatments could reduce mortality, but increase costs by billions

November 19, 2014
BOSTON – In this video exclusive from The Liver Meeting, David B. Rein, PhD, MPA, of the National Opinion…
More »
In the Journals

Chronic HBV prevalent among non-high-risk populations across world

July 31, 2015
In a new study, researchers found a prevalence of chronic hepatitis B virus infection across various non–high-risk populations across the…

AbbVie announces Viekira Pak sales reach nearly $400 million

July 31, 2015
AbbVie announced second quarter financial results and showed Viekira Pak global sales were nearly $400 million, which assisted the company in…

Gilead's product sales soar due to Harvoni

July 30, 2015
Gilead Sciences announced second quarter financial results and showed an increase of $1.7 billion for overall product sales and an increase of $1.6…
In the Journals

Cirrhosis in HCV patients may be underdiagnosed

July 30, 2015
Cirrhosis was found to be underdiagnosed among patients with hepatitis C virus infection enrolled in the Chronic Hepatitis Cohort Study, according to…
New poll shows over 50% of Americans unaware of HBV vaccine

New poll shows over 50% of Americans unaware of HBV vaccine

July 28, 2015
In a new national poll, consultants found that more than 50% of Americans did not know a vaccine for hepatitis B virus infection existed, according…

Seven FDA developments since last World Hepatitis Day

July 28, 2015
World Hepatitis Day is July 28. To acknowledge how far treatment and the drug pipeline for hepatitis C and other strands of the virus infection has…
In the Journals

Opioid tampering by providers who use drugs increases risk for HCV transmission

July 27, 2015
Health care providers with unknown hepatitis C virus infection who injected drugs had a high risk for contributing to nosocomial outbreaks of the…

WHO encourages safe injection use to prevent HBV, HCV

July 27, 2015
In honor of the fifth annual World Hepatitis Day on July 28, the World Health Organization has launched a pilot, global safety injection initiative…
Ed Cox FDA News

FDA approves Daklinza for chronic hepatitis C genotype 3 infections

July 24, 2015
The FDA announced the approval of daclatasvir in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 3…

Janssen submits supplemental new drug application for Olysio

July 24, 2015
Janssen Therapeutics, announced they have submitted a supplemental new drug application to the FDA to update the label for Olysio, its protease…
More Headlines »
morganatic-roan